Status:
COMPLETED
Baricitinib Therapy in COVID-19
Lead Sponsor:
Fabrizio Cantini
Conditions:
COVID
Pneumonia
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
Retrospective study on the efficacy of baricitinib in 12 COVID-19 patients with moderate pneumonia.
Detailed Description
Baricitinib, an anti-Janus kinase inhibitor (anti-JAK) acting against JAK1 and JAK2 that inhibits JAK1- and JAK2-mediated cytokine release, was recently described using BenevolentAI's proprietary arti...
Eligibility Criteria
Inclusion
- SARS-Co-V2 positivitity to the nasal-swab by reverse-transcriptase-polymerase chain- reaction (RT-PCR) assay tested by the local diagnostic laboratory
- Age \>18 and \<85 years
- Presence of at least 3 of the following symptoms as present fever, cough, myalgia, fatigue.
- Presence of radiological findings of pneumonia assessed by chest radiograph, computed tomography, or pulmonary ultrasound.
- Peripheral capillary oxygen saturation (SpO2) \> 92% on room air at screening
- PaO2/FiO2 \>100-300 mmHg at arterial blood gas analysis.
Exclusion
- Age \< 18 and \>85
- History of thrombophlebitis
- Latent tuberculosis infection (based on the positivity to QuantiFERON Plus positivity, Qiagen, Germany)
- Pregnancy and lactation
- History of malignancies over the previous 5 years, current diagnosis of malignancy
- Inability or unwillingness to sign a written consent.
- Transaminases values 4-fold higher than the upper normal limit.
- HBV and HCV positivity.
- Current Herpes zoster infection.
- Evidence of concomitant bacterial infections.
Key Trial Info
Start Date :
March 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 7 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04358614
Start Date
March 16 2020
End Date
April 7 2020
Last Update
April 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fabrizio Cantini
Prato, Tuscany, Italy, 59100